AU2026201003A1 - Crystal forms of a pyridazinone TRPC inhibitor - Google Patents

Crystal forms of a pyridazinone TRPC inhibitor

Info

Publication number
AU2026201003A1
AU2026201003A1 AU2026201003A AU2026201003A AU2026201003A1 AU 2026201003 A1 AU2026201003 A1 AU 2026201003A1 AU 2026201003 A AU2026201003 A AU 2026201003A AU 2026201003 A AU2026201003 A AU 2026201003A AU 2026201003 A1 AU2026201003 A1 AU 2026201003A1
Authority
AU
Australia
Prior art keywords
crystalline form
chloro
phenoxy
fluoro
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2026201003A
Other languages
English (en)
Inventor
Yuejun GAO
Wenfeng Xue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GFB ABC LLC
Original Assignee
GFB ABC LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020272030A external-priority patent/AU2020272030C1/en
Application filed by GFB ABC LLC filed Critical GFB ABC LLC
Priority to AU2026201003A priority Critical patent/AU2026201003A1/en
Publication of AU2026201003A1 publication Critical patent/AU2026201003A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AU2026201003A 2019-04-10 2026-02-11 Crystal forms of a pyridazinone TRPC inhibitor Pending AU2026201003A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026201003A AU2026201003A1 (en) 2019-04-10 2026-02-11 Crystal forms of a pyridazinone TRPC inhibitor

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/CN2019/081985 WO2020206623A1 (en) 2019-04-10 2019-04-10 Crystal forms
AUPCT/CN2019/081985 2019-04-10
AU2020272030A AU2020272030C1 (en) 2019-04-10 2020-04-10 Crystal forms of a pyridazinone TRPC inhibitor
PCT/US2020/027689 WO2020210639A1 (en) 2019-04-10 2020-04-10 Crystal forms of a pyridazinone trpc inhibitor
AU2026201003A AU2026201003A1 (en) 2019-04-10 2026-02-11 Crystal forms of a pyridazinone TRPC inhibitor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2020272030A Division AU2020272030C1 (en) 2019-04-10 2020-04-10 Crystal forms of a pyridazinone TRPC inhibitor

Publications (1)

Publication Number Publication Date
AU2026201003A1 true AU2026201003A1 (en) 2026-03-05

Family

ID=70482847

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2026201003A Pending AU2026201003A1 (en) 2019-04-10 2026-02-11 Crystal forms of a pyridazinone TRPC inhibitor

Country Status (10)

Country Link
US (1) US20220177455A1 (https=)
EP (1) EP3953352A1 (https=)
JP (2) JP7738482B2 (https=)
CN (2) CN114502552B (https=)
AU (1) AU2026201003A1 (https=)
BR (1) BR112021018221A2 (https=)
CA (1) CA3136652A1 (https=)
MA (1) MA55614A (https=)
MX (2) MX2021012313A (https=)
WO (2) WO2020206623A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3684364A4 (en) 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF
MA71645A (fr) * 2018-09-18 2025-05-30 Goldfinch Bio, Inc. Pyridazinones et leurs procédés d'utilisation
US12576033B2 (en) * 2019-04-11 2026-03-17 Gfb (Abc), Llc Spray-dried formulation of a pyridazinone TRPC5 inhibitor
JP2022551580A (ja) * 2019-10-04 2022-12-12 ゴールドフィンチ バイオ，インク． 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置
JP7539545B2 (ja) * 2020-07-03 2024-08-23 武漢朗来科技発展有限公司 複素環化合物及びその使用
US20250122190A1 (en) * 2021-09-10 2025-04-17 Medshine Discovery Inc. Halogen-substituted pyridazinone compound and application thereof
US20250082655A1 (en) * 2022-01-27 2025-03-13 Wuhan Createrna Science And Technology Co., Ltd. Use of heterocyclic compound
WO2024027752A1 (zh) * 2022-08-05 2024-02-08 武汉朗来科技发展有限公司 包含杂环化合物的药物组合物及其制备方法和应用
WO2025250920A1 (en) 2024-05-31 2025-12-04 Gfb (Abc), Llc Pyridazinone phosphate compounds, pharmaceutical compositions, and medical uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP310798A0 (en) * 1998-04-22 1998-05-14 Soltec Research Pty Ltd Vehicle system for a composition comprising a piperidinopyrimidine derivative
US8633233B2 (en) * 2008-08-06 2014-01-21 Hydra Biosciences, Inc. Methods and compositions for treating anxiety
WO2016023830A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
EP3684364A4 (en) * 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF
MA71645A (fr) * 2018-09-18 2025-05-30 Goldfinch Bio, Inc. Pyridazinones et leurs procédés d'utilisation

Also Published As

Publication number Publication date
JP7738482B2 (ja) 2025-09-12
AU2020272030B2 (en) 2025-11-13
AU2020272030A1 (en) 2021-11-11
MX2021012313A (es) 2021-11-17
CN114502552A (zh) 2022-05-13
MX2025006384A (es) 2025-07-01
JP2022525759A (ja) 2022-05-19
CN119264134A (zh) 2025-01-07
EP3953352A1 (en) 2022-02-16
MA55614A (fr) 2022-02-16
CN114502552B (zh) 2024-08-16
BR112021018221A2 (pt) 2022-01-18
US20220177455A1 (en) 2022-06-09
WO2020206623A1 (en) 2020-10-15
WO2020210639A1 (en) 2020-10-15
CA3136652A1 (en) 2020-10-15
JP2026004294A (ja) 2026-01-14

Similar Documents

Publication Publication Date Title
AU2026201003A1 (en) Crystal forms of a pyridazinone TRPC inhibitor
CN114040913B (zh) 哒嗪酮trpc5抑制剂的喷雾干燥制剂
JP2025183335A (ja) 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置
JP2003533477A (ja) リン酸輸送阻害剤
TW200817401A (en) KW-3902 conjugates that do not cross the blood-brain barrier
JP2004534760A (ja) 腎線維症の治療
KR100310665B1 (ko) 피부질환치료용약제학적조성물
AU2020272030C1 (en) Crystal forms of a pyridazinone TRPC inhibitor
HK40122791A (zh) 哒嗪酮trpc抑制剂的晶体形式
KR102956339B1 (ko) 피리다진온 trpc5 억제제의 분무 건조된 제형
BR122025019562A2 (pt) Formas cristalinas de um inibidor de trpc de piridazinona, composição farmacêutica que as compreende e uso das mesmas
AU2020293524B2 (en) Potassium salt crystal form B of phosphodiesterase type 5 inhibitor, and preparation method and use therefor
CZ182895A3 (en) Lysine salt of 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide per se and for treating diseases, and pharmaceutical composition based thereon
BR122025019564A2 (pt) Dispersão seca por pulverização, composição para sua formulação e método de fabricação da mesma, forma de dosagem sólida e seu método de fabricação, e uso de um inibidor de piridazinona trpc5 para tratar dor, ansiedade ou depressão
KR20260059680A (ko) 피리다진온 trpc5 억제제의 분무 건조된 제형
CN118043050A (zh) 用固体形式的比托哌汀治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法
WO2026067059A1 (zh) Jak2抑制剂在制备治疗慢性肾脏病的药物中的用途
TW200522962A (en) Neutrophilia inhibitor
MXPA06010416A (en) Use of organic compounds
SI9400099A (sl) Lizinova sol 6-kloro-5-fluoro-3-{2-tenoil)-2-oksindol-1-karboksiamida